CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

NCT02912455 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Study was terminated due to difficulty with reaching enrollment goals

Conditions

Diabetes Mellitus, Type 2
Obesity

Interventions

DRUG: canagliflozin
DRUG: Placebo (for canagliflozin)

Sponsor

The Cleveland Clinic

Collaborators

[object Object]